Wall Street brokerages expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report $2.52 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $440,000.00 and the highest is $7.00 million. BioCryst Pharmaceuticals posted sales of $12.49 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 79.8%. The business is expected to report its next earnings results on Tuesday, August 6th.

On average, analysts expect that BioCryst Pharmaceuticals will report full year sales of $16.86 million for the current fiscal year, with estimates ranging from $9.79 million to $27.00 million. For the next year, analysts anticipate that the firm will post sales of $42.53 million, with estimates ranging from $20.00 million to $89.46 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). BioCryst Pharmaceuticals had a negative return on equity of 223.34% and a negative net margin of 472.12%. The firm had revenue of $5.89 million during the quarter, compared to analyst estimates of $2.92 million.

A number of research analysts have commented on the company. Barclays set a €16.80 ($19.53) target price on Deutsche Telekom and gave the stock a “neutral” rating in a report on Tuesday, April 2nd. Jefferies Financial Group reduced their target price on BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 22nd. Zacks Investment Research raised Garrett Motion from a “sell” rating to a “hold” rating in a report on Friday, May 10th. JMP Securities reduced their target price on BioCryst Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday, May 23rd. Finally, ValuEngine raised Westpac Banking from a “sell” rating to a “hold” rating in a report on Wednesday, May 22nd. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $9.56.

NASDAQ BCRX traded down $0.09 during mid-day trading on Friday, reaching $3.39. 631,162 shares of the company’s stock traded hands, compared to its average volume of 1,515,484. BioCryst Pharmaceuticals has a 1-year low of $2.80 and a 1-year high of $9.95. The firm’s fifty day simple moving average is $3.58. The company has a current ratio of 1.77, a quick ratio of 1.76 and a debt-to-equity ratio of 2.38. The stock has a market capitalization of $373.96 million, a P/E ratio of -3.46 and a beta of 2.05.

In related news, CFO Thomas R. Staab II sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $7.75, for a total value of $69,750.00. Following the sale, the chief financial officer now owns 140,426 shares of the company’s stock, valued at approximately $1,088,301.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Thomas R. Staab II sold 11,750 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $7.81, for a total value of $91,767.50. Following the completion of the sale, the insider now directly owns 137,176 shares in the company, valued at approximately $1,071,344.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 67,500 shares of company stock worth $517,223. 5.20% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Paloma Partners Management Co bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $84,000. Amalgamated Bank bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $122,000. Summit Securities Group LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $132,000. Legal & General Group Plc lifted its holdings in shares of BioCryst Pharmaceuticals by 14.5% in the 4th quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 2,453 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $169,000. 91.96% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: How does a reverse stock split work?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.